US Stem Cell's gross profit for the
three
months ended in Dec. 2022 was $0.02 Mil. US Stem Cell's gross profit for the trailing twelve months (TTM) ended in Dec. 2022 was $0.06 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. US Stem Cell's gross profit for the
three
months ended in Dec. 2022 was $0.02 Mil. US Stem Cell's Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil. Therefore, US Stem Cell's Gross Margin % for the quarter that ended in Dec. 2022 was 75.00%.
US Stem Cell had a gross margin of 75.00% for the quarter that ended in Dec. 2022 => Durable competitive advantage
US Stem Cell Gross Profit Historical Data
The historical data trend for US Stem Cell's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Gross Profit
For the Biotechnology subindustry, US Stem Cell's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Gross Profit distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Gross Profit falls into.
US Stem Cell Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
US Stem Cell's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
US Stem Cell (OTCPK:USRM) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
US Stem Cell had a gross margin of 75.00% for the quarter that ended in Dec. 2022 => Durable competitive advantage
US Stem Cell Gross Profit Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 